Search
Graduate Education
Clinical Oncology Year 2019 in Review Presentations
… MD Updates in Management of GI Malignancies / Christos Fountzilas, MD Updates in Lung Cancer Treatments / Edwin Yau, … MD Updates in Management of GI Malignancies / Christos Fountzilas, MD Updates in Lung Cancer Treatments / Edwin Yau, …
Graduate Education
Clinical Oncology Year 2019 in Review Presentations
… MD Updates in Management of GI Malignancies / Christos Fountzilas, MD Updates in Lung Cancer Treatments / Edwin Yau, … MD Updates in Management of GI Malignancies / Christos Fountzilas, MD Updates in Lung Cancer Treatments / Edwin Yau, …
Clinical Trial
A Phase III, Randomized, Controlled, Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician s Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR)-altered, Chemotherapy- and FGFR Inhibitor…
… (FGFR)-altered, Chemotherapy- and FGFR Inhibitor… III Fountzilas, Christos This study is a Phase III, Randomized, …
Page with Layout
Bakin Lab Publications
… B, Foster BA, Rajan P, Attwood K, Chatley S, Iyer R, Fountzilas C, Bakin AV. Citation: Cell Rep Med. 2024 Mar … Smith B, Melnick M, Eng KH, Melendy T, Park BH, Iyer R, Fountzilas C, Bakin AV. Citation: Commun Biol. 2021 Jul …
Clinical Trial
A Phase 1, Open-Label, Dose Escalation and Expansion, Multicenter Study of Claudin 18.2 Targeted Chimeric Antigen Receptor T-cells in Subjects with Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or…
… Gastroesophageal Junction (GEJ), Esophageal, or… I Fountzilas, Christos This is a Phase 1, Open-Label, Dose …
News
Roswell Park Clinical Trials Add Beta Blocker to Arsenal Against Esophageal Cancer
… chemotherapy, and it becomes progressive.” Dr. Christos Fountzilas “Roswell Park is at the forefront of research on … and radiation in those patients,” says Christos Fountzilas, MD, FACP , Co-Leader of the Gastrointestinal … chemotherapy, and it becomes progressive.” Dr. Christos Fountzilas “Roswell Park is at the forefront of research on …
Blog Post
What's New in Pancreatic Cancer Research?
… to treat it. “We should always have hope,” says Christos Fountzilas, MD, FACP , Department of Medical Oncology at … existing therapy. Some of the latest developments that Dr. Fountzilas considers exciting are new agents that target the … efforts from basic and clinical cancer researchers, Dr. Fountzilas explains. “Blocking a single pathway is not …
Clinical Trial
HERTHENA-PanTumor01 (U31402-277): A Phase 2, Multicenter, Multicohort, Open-Label, Proof of Concept Study of Patritumab Deruxtecan (HER3-DXd; U3-1402) in Subjects with Locally Advanced or Metastatic Solid Tumors
… with Locally Advanced or Metastatic Solid Tumors II Fountzilas, Christos This is a proof-of-concept study …
Clinical Trial
A Phase I Study of Trifluridine/ Tipiracil plus the Poly (ADP) Ribose Polymerase Inhibitor Talazoparib in Advanced Cancers
… Polymerase Inhibitor Talazoparib in Advanced Cancers I Fountzilas, Christos This phase I trial investigates the side …
News
Roswell Park Study First to Show Two-Drug Combination Selectively Targets p53-Mutant Cancers
… in the United States,” notes study co-author Christos Fountzilas, MD, FACP , Co-Leader of the Gastrointestinal … Recognizing the need for better therapeutic options, Dr. Fountzilas and his colleague, Andrei V. Bakin, PhD , … for selective targeting of p53-mutant cancers,” Dr. Fountzilas adds. “Of note, while PARP inhibitors are approved …